GlobeNewswire

SignalFx Raises $75 Million to Fuel Demand for its Cloud Monitoring Platform

Del

SAN MATEO, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- SignalFx, the leader in real-time cloud monitoring and observability for infrastructure, microservices, and applications, today announced it has raised $75 million in Series E funding led by Tiger Global Management with participation from existing investors. The primary equity financing brings total funding raised to $179 million and will accelerate product development and the company’s rapid global expansion.

SignalFx’s growth comes as organizations have increasingly turned to cloud-native technologies such as microservices, containers, Kubernetes and serverless functions to speed their rate of innovation. SignalFx’s annual revenues have increased by a compound annual growth rate of 170 percent since sales began in 2015 as traditional monitoring tools have failed to keep pace with new requirements for speed, scale and automation. According to Gartner, by 2022, more than 75 percent of global organizations will be running containerized applications in production, up from fewer than 30 percent today.

SignalFx’s customer list has grown to include hundreds of market-leading brands in an array of industry verticals and geographies, from ecommerce, retail, transportation, enterprise, and technology to finance, consumer products, and health care. Customers include both high-tech organizations born in the cloud, such as Acquia, Carbon Black, Cloudreach, Freecharge, HubSpot, Kayak, Namely, Rappi, Shutterfly, Square, and Yelp, as well as traditional enterprises investing in digital transformation, such as Amtrak, athenahealth, Lululemon, NBCUniversal, and the Warehouse Group.

“The addition of Tiger Global Management to our team comes at an important time for SignalFx,” said Karthik Rau, CEO, SignalFx. “SignalFx is at an inflection point in its growth as organizations are investing aggressively in their cloud and digital transformation initiatives and reevaluating their systems management and monitoring strategies. The additional capital from this financing allows us to invest even more in our industry-leading products while also extending our go-to-market reach to more organizations around the world.” 

SignalFx pioneered the use of streaming analytics for monitoring cloud infrastructure and applications, building a highly scalable, low latency platform that can process massive amounts of data using advanced data science to accurately identify patterns of behavior and alert on anomalies in seconds. In November the company further increased the technical leadership of its platform by adding Microservices APM™, the industry’s first real-time application performance monitoring solution designed to accelerate the troubleshooting and triaging of microservices-based applications. Microservices APM is powered by a unique NoSample™ architecture that observes every transaction—instead of just a small random sample—and accurately reports on every anomaly.

SignalFx was founded in 2013 by the original developers of Facebook’s metrics-based monitoring solution (ODS), one of the industry’s first DevOps monitoring platforms. During the last two years, the company has expanded its executive bench to include: Chief Operating Officer Mark Cranney, Chief Financial Officer Mark Resnick, Executive Vice President of Engineering Leonid Igolnik, Chief Marketing Officer Tom Butta, and Chief People Officer Laura MacKinnon.

In February, SignalFx announced the opening of a Research and Development Support Office in Krakow, Poland and expanded sales operations throughout EMEA and Australia. Global headcount is now 270 and growing.

About SignalFx

SignalFx, the only real-time cloud monitoring platform for infrastructure, microservices, and applications, collects and analyzes metrics and traces across every component in your cloud environment. Built on a massively scalable streaming architecture, SignalFx applies advanced analytics and data-science-directed troubleshooting to let operators find the root cause of issues in seconds. SignalFx is trusted by leading enterprises across most every industry sector. SignalFx is backed by Andreessen Horowitz, Charles River Ventures, General Catalyst, and Tiger Global Management.

For More Information:

Contact Mike Moeller, (408) 439-4169

*Gartner, Inc., Best Practices for Running Containers and Kubernetes in Production, Arun Chandrasekaran, 25 February 2019.

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi